ARTICLE
4 January 2010

Interim Period For Borderline Products Expires

CC
CMS Cameron McKenna Nabarro Olswang

Contributor

CMS is a Future Facing firm with 79 offices in over 40 countries and more than 5,000 lawyers globally. Combining local market insight with a global perspective, CMS provides business-focused advice to help clients navigate change confidently. The firm's expertise and innovative approach anticipate challenges and develop solutions. CMS is committed to diversity, inclusivity, and corporate social responsibility, fostering a supportive culture. The firm addresses key client concerns like efficiency and regulatory challenges through services like Law-Now, offering real-time eAlerts, mobile access, an extensive legal archive, specialist zones, and global events.

The interim period for borderline products will expire on 31 December 2009 after attempts to extend it failed.
Poland Food, Drugs, Healthcare, Life Sciences

The interim period for borderline products will expire on 31 December 2009 after attempts to extend it failed.

The interim period applies to products that:

  • were placed on the market in Poland before 1 May 2007
  • satisfied the criteria of medicinal products and other product categories (such as dietary supplements) on the day they were placed on the market

The expiry of the interim period has no official interpretation. In particular, it is not clear if borderline products could be placed on the market after 31 December 2009 or must be withdrawn from the market after this date.

As there are no clear criteria for distinguishing between borderline and medicinal products (in particular with regard to herbal products) an analysis of individual products is necessary.

Where there are doubts whether a borderline product meets the criteria for medicinal products, this would be made in the course of clearance proceedings conducted by the sanitary inspection.

This means that, where the interim period applies, there is no basis for withdrawing borderline products from the market without an assessment.

Where a product is shown in clearance proceedings to meet the criteria for medicinal products, it will be withdrawn from the market subject to a right of appeal by the business responsible for putting it on the market.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to www.law-now.com/law-now/mondaq

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 30/12/2009.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More